ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 99.10% (As of Jun. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ASLAN Pharmaceuticals's float shares is 22.43 Mil. ASLAN Pharmaceuticals's total shares outstanding is 22.63 Mil. ASLAN Pharmaceuticals's float percentage of total shares outstanding is 99.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ASLAN Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ASLAN Pharmaceuticals's Institutional Ownership is 0.13%.

ASLAN Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ASLAN Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	22.43	/	22.63
	=	99.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190

Website

https://www.aslanpharma.com

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.